Penumbra Coil System Penumbra Coil 400
FDA Clearance Information
The Penumbra Coil System 400 was cleared by the FDA via the 510(k) pathway on April 2, 2012. It is manufactured by Penumbra and classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- Embolization of intracranial aneurysms.
- Embolization of other neurovascular abnormalities, including arteriovenous fistulas, when treatment with a detachable coil is appropriate.
- Mechanical occlusion of blood vessels during endovascular embolization procedures.
Clinical Applications
- Endovascular coiling of selected brain aneurysms.
- Embolization of selected intracranial or other neurovascular arteriovenous fistulas.
- Targeted vessel occlusion when an interventional specialist needs to stop or reduce blood flow to a defined vascular area.
Reported off-label uses
- Embolization of selected peripheral visceral or pelvic arteries, such as treatment of aneurysms, pseudoaneurysms, or active bleeding, depending on the specific coil configuration and clinical judgment.
- Embolization of selected arteriovenous malformations outside the central nervous system.
Off-label use: these uses are reported in practice or the literature but are not part of the FDA-cleared indications. Physicians may use a cleared device off-label based on their medical judgment; the manufacturer may not promote off-label uses.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The system includes detachable coils in multiple diameters and lengths; the treating physician selects the size based on the target vessel, aneurysm or fistula anatomy, and desired packing density.
- Coil delivery requires a compatible microcatheter and fluoroscopic or angiographic imaging. Vessel access is commonly obtained through the femoral or radial artery, depending on the procedure.
- Patients with infection at the access site, severe bleeding or clotting problems, or anatomy that cannot safely accommodate the catheter and coil may not be candidates.
- MRI safety depends on the exact coil model, implantation conditions, and the manufacturer's current labeling. The implant identification card and official instructions for use should be reviewed before MRI.
- The coil is intended to remain permanently implanted. Possible complications include bleeding, vessel injury, clot formation, unintended vessel occlusion, coil migration, aneurysm recurrence, infection, and procedure-related neurologic injury.
Procedures that use this device
Linked Studies (7)
OnyxTMGel or Coil versus Hydrogel as Embolic Agents in Endovascular Applications: Review of the Literature and Case Series.
Gels (Basel, Switzerland)
View Source →The SMART Registry: Long-Term Results on the Utility of the Penumbra SMART COIL System for Treatment of Intracranial Aneurysms and Other Malformations.
Frontiers in neurology
Prospective View Source →The penumbra coil 400 system for treatment of wide-necked intracranial aneurysms: initial single-center experience.
Acta neurochirurgica. Supplement
Other View Source →Initial experience using the Penumbra coil 400: comparison of aneurysm packing, cost effectiveness, and coil efficiency.
Journal of neurointerventional surgery
Retrospective View Source →Initial experience with Penumbra Coil 400 versus standard coils in embolization of cerebral aneurysms: a retrospective review.
Journal of neurointerventional surgery
Retrospective View Source →CARE: A Prospective Multicenter Case Study to Assess Radiation Exposure in Patients Treated With the Penumbra Coil 400
View Source →Frequently Asked Questions
What are the clinical indications for Penumbra Coil System Penumbra Coil 400?
The device is indicated for use in mechanical thrombectomy and embolization procedures, particularly for treating intracranial aneurysms and arteriovenous fistulas.
What outcomes have been reported in clinical studies?
Clinical studies have reported a 6.8% retreatment rate at 1 year and a 90.0% rate of achieving Raymond Roy Occlusion Classification I or II for aneurysms.
What complications have been reported?
Safety data indicate a 2.6% rate of procedural device-related serious adverse events.